Ectopic Fat, Insulin Resistance, and Nonalcoholic Fatty Liver Disease Implications for Cardiovascular Disease
Ectopic Fat, Insulin Resistance, and Nonalcoholic Fatty Liver Disease Implications for Cardiovascular Disease
复制标题
异位脂肪、胰岛素抵抗和非酒精性脂肪肝对心血管疾病的影响
DOI:
10.1161/atvbaha.114.303034
复制
发表时间:
2014-06-01
影响因子:
8.7
通讯作者:
Targher, Giovanni
中科院分区:
文献类型:
--
作者:
Byrne, Christopher D.;Targher, Giovanni
Ectopic fat accumulation in the liver causes nonalcoholic fatty liver disease (NAFLD), which is the most common cause of chronic liver disease in Western countries. Ectopic liver lipid, particularly diacylglycerol, exacerbates hepatic insulin resistance, promotes systemic inflammation, and increases risk of developing both type 2 diabetes mellitus and cardiovascular disease. Increasing evidence suggests that NAFLD is an emerging risk factor for cardiovascular disease, and although there are currently no licensed treatments for NAFLD per se, current evidence suggests that statin treatment is safe in NAFLD. Presently, there is insufficient evidence to indicate that statins or other cardioprotective agents, such as angiotensin receptor blockers, are effective in treating NAFLD. In this brief narrative review, we discuss the diagnosis of NAFLD and the role of ectopic liver fat to cause insulin resistance and to increase risk of both type 2 diabetes mellitus and cardiovascular disease. For this review, PubMed was searched for articles using the key words non-alcoholic fatty liver disease or fatty liver combined with diabetes risk, cardiovascular risk, and cardiovascular mortality between 1990 and 2014. Articles published in languages other than English were excluded.